Srinivas Akkaraju - Feb 14, 2023 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role: Director, 10%+ Owner
Signature: /s/ Srinivas Akkaraju
Stock symbol: MLYS
Transactions as of: Feb 14, 2023
Transactions value $: $15,000,000
Form type: 4
Date filed: 2/16/2023, 03:54 PM
Previous filing: Feb 9, 2023
Next filing: May 25, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLYS	Common Stock	Conversion of derivative security		+3.58M			3.58M	Feb 14, 2023	See footnote	F1, F2
transaction	MLYS	Common Stock	Purchase	$15M	+938K	+26.17%	$16.00	4.52M	Feb 14, 2023	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MLYS	Series A Preferred Stock	Conversion of derivative security	$0	-2.14M	-100%	$0.00^*	0	Feb 14, 2023	Common Stock	2.14M		See footnote	F1, F2
transaction	MLYS	Series B Preferred Stock	Conversion of derivative security	$0	-1.45M	-100%	$0.00^*	0	Feb 14, 2023	Common Stock	1.45M		See footnote	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.
F2	Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.

Content

Each share of preferred stock of the Issuer automatically converted into shares of common stock on a 10.798-for-one basis (which reflects the reverse stock split effected by the Issuer on February 1, 2023) upon closing of the Issuer's initial public offering.

Represents securities held directly by Samsara BioCapital, L.P. Samsara BioCapital GP, LLC ("Samsara LLC") is the general partner of Samsara BioCapital, L.P. ("Samsara LP") and may be deemed to beneficially own the shares held by Samsara LP. Dr. Akkaraju has voting and investment power over the shares held by Samsara LP and, accordingly, may be deemed to beneficially own the shares held by Samsara LP. Each of Samsara LLC and Dr. Akkaraju disclaims beneficial ownership in these shares except to the extent of his or its respective pecuniary interest therein.